Review ArticleReviews
Antiangiogenic Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: Focusing on Regorafenib
MARIOS PAPADIMITRIOU and CHRISTOS A. PAPADIMITRIOU
Anticancer Research February 2021, 41 (2) 567-582; DOI: https://doi.org/10.21873/anticanres.14809
MARIOS PAPADIMITRIOU
Oncology Unit, Second Department of Surgery, “Aretaieion” University Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece
CHRISTOS A. PAPADIMITRIOU
Oncology Unit, Second Department of Surgery, “Aretaieion” University Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece
In this issue
Anticancer Research
Vol. 41, Issue 2
February 2021
Antiangiogenic Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: Focusing on Regorafenib
MARIOS PAPADIMITRIOU, CHRISTOS A. PAPADIMITRIOU
Anticancer Research Feb 2021, 41 (2) 567-582; DOI: 10.21873/anticanres.14809
Jump to section
- Article
- Abstract
- Regorafenib: Structure and Mechanism of Action
- Phase II and III Clinical Trials With Regorafenib Monotherapy
- Observational Studies With Regorafenib Monotherapy in the Real-World Setting
- Retrospective Analyses Comparing Regorafenib With TAS-102
- Dose-escalation Trials of Regorafenib
- Regorafenib in Elderly Patients
- Regorafenib in Combination With Chemotherapy
- Combination of Regorafenib With Immune Checkpoint Inhibitors
- Systematic Reviews and Meta-analyses of Regorafenib Trials
- Other TKIs in mCRC
- Conclusion
- Footnotes
- References
- Figures & Data
- Info & Metrics
Related Articles
- No related articles found.